Phase 2 Data for Roche’s Lymphoma ADC Doesn’t Disappoint
With breakthrough designation from the FDA and priority medicine status in the EU, expectations for Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab vedotin are running pretty high. Phase 2 data presented atRead More…